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Minimum Clinical Recommendations for diagnosis, treatment
and follow-up of newly diagnosed follicular lymphoma
Incidence
. Follicular lymphomas present worldwide the second most
frequent subtype of nodal lymphoid malignancies.
. The incidence of this disease has rapidly increased during
recent decades and has risen from 2–3/100 000/year during
the 1950 s to more than 5–7/100 000/year recently.
Diagnosis
. Diagnosis should always be based on a surgical specimen/
excisional lymph node biopsy providing enough material
for fresh frozen and formalin-fixed samples [II, A].
To ensure adequate quality, immediate processing by an
experienced pathology institute has to be guaranteed. Fine
needle aspirations or core biopsies are inappropriate for
a proper diagnosis and should only be used in the rare
patients requiring emergency treatment.
. The histological report should give the diagnosis according
to the World Health Organisation classification.
Staging and risk assessment
. Since treatment substantially depends on the stage of the
disease, initial staging should be thorough particularly in the
small proportion of patients with early stages I and II (15–
20%). Initial work-up should include a CT-scan of the
thorax, abdomen and pelvis, and a bone marrow aspirate
and biopsy [IV, C]. A complete blood count, routine blood
chemistry including LDH and uric acid as well as screening
tests for HIV and hepatitis B and C are required.
. The staging is given according to the Ann Arbor system
with mentioning of bulky disease.
. For prognostic purposes, a Follicular Lymphoma-specific
International Prognostic Index (FLIPI) has been recently
recommended [III, B].
Treatment plan
Stage I
. In the small proportion of patients with limited stages I,
radiotherapy is the treatment of choice with a curative
potential. Radiotherapy should be performed as extended
field irradiation [II, B].
. In selected patients with large tumor burden systemic
therapy as developed for advanced stages may also be used
[IV, B].
Stage II–IV
. In the large proportion of patients with advanced stage III
and IV disease no curative therapy is yet established. Since
the natural course of the disease is characterized by spon-
taneous regressions in 15–20% of cases and varies from
case to case, chemotherapy should be initiated only upon
the occurrence of symptoms including B-symptoms, hema-
topoietic impairments, bulky disease or lymphoma pro-
gression [II, B].
. If complete remission and long progression-free survival is
to be achieved, rituximab in combination with chemother-
apy (COP, CHOP and fludarabine-containing schemes such
as FCM) should be considered [I, B]. Single agent fludara-
bine or chlorambucil remain an alternative [III, B]. In
selected cases with contraindications for chemotherapy,
antibody monotherapy alone may be discussed [II, B].
Consolidation
. Meta-analysis suggests a survival benefit with interferon-a
as maintenance therapy that has to be balanced against tox-
icity. Rituximab prolonged progression-free survival in a
randomized trial. Myeloablative radiochemotherapy fol-
lowed by autologous stem cell transplantation remains
investigational [I, B].
. Radio-immunotherapy and potentially curative allogeneic
stem cell transplantation may be discussed especially in
second and higher relapses.
Response evaluation
. Adequate radiological tests should be done after ever 2–3
cycles of therapy and after completion of chemotherapy.
Patients with incomplete or lacking response should be eval-
uated for early salvage regimens.
Follow-up
. History and physical examination every 3 months for 2
years, every 6 months for 3 additional years, and sub-
sequently once a year with special attention to transform-
ation and secondary malignancies including secondary
leukemia [V, D].
. Blood count at 3, 6, 12 and 24 months, then only as needed
for evaluation of suspicious symptoms.
. Evaluation of thyroid function in patients with irradiation to
the neck at 1, 2 and 5 years.
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. Minimal adequate radiological or ultrasound examinations
at 6, 12 and 24 months after end of treatment.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
Literature
1. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma
international prognostic index. Blood 2004; 104: 1258–1265.
2. MacManus PM, Hoppe RT. Is radiotherapy curative for stage I and
II low grade follicular lymphoma? Results of a long term follow-up
study of patients treated at Stanford University. J Clin Oncol 1996;
14: 1282–1290.
3. Stuschke M, Hoederath A, Sack H. Extended field and total central
lymphatic radiotherapy for early stages nodal centroblastic-centrocy-
tic lymphoma: Results of a prospective multicenter study. Cancer
1997; 80: 2273–2284.
4. Horning SJ, Rosenberg SA. The natural history of initially untreated
low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311:
1471–1475.
5. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus Rituxi-
mab compared with CVP as first-line treatment for advanced follicu-
lar lymphoma. Blood 2005; 105: 1417–1423.
6. Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment
with rituximab in patients with follicular lymphoma significantly
increases event-free survival and response duration compared with
the standard weekly 4 schedule. Blood 2004; 103: 4416–4423.
Coordinating authors for the ESMO Guidelines Task Force:
W. Hiddemann1, M. Dreyling1 & R. A. Stahel2
1Invited authors, Klinikum Grosshadern, Med. Klinik III,
Ha¨matologie/Onkologie, Marchioninstrasse 5, D-81377 Mu¨nchen,
Germany; 2Assigned task force member, Div. of Oncology, University
Hospital, Ra¨mistr. 100, CH-8091 Zu¨rich, Switzerland
Approved by the ESMO Guidelines Task Force: August 2002, last update
December 2004.
Correspondence to:
ESMO Guidelines Task Force
ESMO Head Office
Via La Santa 7
CH-6962 Viganello-Lugano
Switzerland
i57
